Mary Wilson
Well-known member
Available online 23 June 2023
https://doi.org/10.1016/j.vaccine.2023.06.069
K. Torp Hansen [SUP]a[/SUP] [SUP]1[/SUP], F. Kusk Povlsen [SUP]a[/SUP] [SUP]b[/SUP] [SUP]1[/SUP], B. Hammer Bech [SUP]a[/SUP], S. Nygaard Hansen [SUP]a[/SUP], C. Ulrikka Rask [SUP]c[/SUP] [SUP]d[/SUP], P. Fink [SUP]c[/SUP] [SUP]e[/SUP], T. Jørgensen [SUP]f[/SUP] [SUP]g[/SUP], H. Nielsen [SUP]h[/SUP] [SUP]i[/SUP], T. Meinertz Dantoft [SUP]f[/SUP], S. Marie Thysen [SUP]f[/SUP], D. Rytter [SUP]a[/SUP]
Abstract
Introduction
There is sparse knowledge of immediate adverse reactions following COVID-19 vaccination.
Objective
This study aimed to estimate the frequency and number of immediate adverse reactions following COVID-19 vaccination in a Danish population.
Methods
The study used data from the Danish population-based cohort study BiCoVac. The frequencies of 20 self-reported adverse reactions were estimated for each vaccine dose stratified by sex, age, and vaccine type. Also, the distributions of number of adverse reactions following each dose were estimated stratified by sex, age, vaccine type, and prior COVID-19 infection.
Results
A total of 889,503 citizens were invited and 171,008 (19%) vaccinated individuals were included in the analysis. The most frequently reported adverse reaction following the first dose of COVID-19 vaccine was redness and/or pain at the injection site (20%) while following the second and third dose, tiredness was the most frequently reported adverse reaction (22% and 14%, respectively). Individuals aged 26-35 years, females, and those with a prior COVID-19 infection were more likely to report adverse reactions compared with older individuals, males, and those with no prior COVID-19 infection, respectively. Following the first dose, individuals vaccinated with ChAdOx1-2 (AstraZeneca) reported more adverse reactions compared with individuals vaccinated with other vaccine types. Individuals vaccinated with mRNA-1273 (Moderna) reported more adverse reactions following the second and third dose compared with individuals vaccinated with BNT162b2 (Pfizer-BioNTech).
Conclusion
The frequency of immediate adverse reactions was highest among females and younger persons, however, most of the Danish citizens did not experience immediate adverse reactions following COVID-19 vaccination.
https://www.sciencedirect.com/science/article/pii/S0264410X23007582
https://doi.org/10.1016/j.vaccine.2023.06.069
K. Torp Hansen [SUP]a[/SUP] [SUP]1[/SUP], F. Kusk Povlsen [SUP]a[/SUP] [SUP]b[/SUP] [SUP]1[/SUP], B. Hammer Bech [SUP]a[/SUP], S. Nygaard Hansen [SUP]a[/SUP], C. Ulrikka Rask [SUP]c[/SUP] [SUP]d[/SUP], P. Fink [SUP]c[/SUP] [SUP]e[/SUP], T. Jørgensen [SUP]f[/SUP] [SUP]g[/SUP], H. Nielsen [SUP]h[/SUP] [SUP]i[/SUP], T. Meinertz Dantoft [SUP]f[/SUP], S. Marie Thysen [SUP]f[/SUP], D. Rytter [SUP]a[/SUP]
Abstract
Introduction
There is sparse knowledge of immediate adverse reactions following COVID-19 vaccination.
Objective
This study aimed to estimate the frequency and number of immediate adverse reactions following COVID-19 vaccination in a Danish population.
Methods
The study used data from the Danish population-based cohort study BiCoVac. The frequencies of 20 self-reported adverse reactions were estimated for each vaccine dose stratified by sex, age, and vaccine type. Also, the distributions of number of adverse reactions following each dose were estimated stratified by sex, age, vaccine type, and prior COVID-19 infection.
Results
A total of 889,503 citizens were invited and 171,008 (19%) vaccinated individuals were included in the analysis. The most frequently reported adverse reaction following the first dose of COVID-19 vaccine was redness and/or pain at the injection site (20%) while following the second and third dose, tiredness was the most frequently reported adverse reaction (22% and 14%, respectively). Individuals aged 26-35 years, females, and those with a prior COVID-19 infection were more likely to report adverse reactions compared with older individuals, males, and those with no prior COVID-19 infection, respectively. Following the first dose, individuals vaccinated with ChAdOx1-2 (AstraZeneca) reported more adverse reactions compared with individuals vaccinated with other vaccine types. Individuals vaccinated with mRNA-1273 (Moderna) reported more adverse reactions following the second and third dose compared with individuals vaccinated with BNT162b2 (Pfizer-BioNTech).
Conclusion
The frequency of immediate adverse reactions was highest among females and younger persons, however, most of the Danish citizens did not experience immediate adverse reactions following COVID-19 vaccination.
https://www.sciencedirect.com/science/article/pii/S0264410X23007582